Pharmaceutical compounds containing these compounds, and procedures for using these compounds to treat diseases or diseases related to uncontrolled or inappropriate stimulation of the crth2.requirement function: a formula compound (1),Or an acceptable table salt, in which j1and J2 are independent of C (H),C (R1),C (R22)O n is applicable to the following conditions: (I) n is not more than j 1 and j 2, (II) C (r 22) is not more than j 1 and j 2；Only one R1 of Y (I I I) is replaced in the diagram circle containing j 1 and j 2； R1 is selected from group (I) - C (o) - n (r6a) (R6b),(Ii) -S (O) 2-N (R6a) (R6b)(Iii) -C (O) -C (R7a) (R7b) (R7c)(Iv) -N (H) -C (O) -C (R7a) (R7b) (R7c)(V) -C (O) -O-C (R7a) (R7b) (R7c)y (vi) -N (H) -S (O) 2-C (R7a) (R7b) (R7c)R6a and R6b are independent: (a) h, (b) C1-6 Baibai formation, (c) C 3-6 Baibai formation, (d) C3-6 Baibai formation, (E) - or - (c1-3 Baibai formation),(f) Q-rah, RAH is a phenyl or 5-6 isomer, which contains 1-2 heteroatoms independently selected from n, O and s groups. RAH has not been replaced or replaced by 1-5 R8 residues independently selected from halogenation, c1-3 tar, alcoxi c1-3 groups, C1-3, - O - (c1-3 fluoropropyl)Hydroxyl, phenyl, and CN； Q selected from the group consisting of (a) links； (b) C 1-6 tar, where C1-6 tar is not replaced or replaced by 1 to 2 fluorine, c1-3 tar, c1-3 hydroxide compound, or c1-3 fluorine； and (c) other formula (2),T is 1, 2, 3 or 4； g-q-rhc, wherein RHC is (I) 5-7 non cyclized substance containing a heteroatom selected from groups n, O, s, s (o) and S (o), in which the non cyclized substance of RHC can be selectively concentrated with benzene, pyridyl ring or (II) cyclopropyl compound c3-7, The RHC cyclopentadiene is selectively concentrated with benzene or pyridine ring； in this case, the RHC is not replaced or replaced by one to five R12 residues selected separately from halides, c1-3 tar, alcoxi c1-3, c1-3 quinolo fluoride or - (c1-3 quilo fluoride),Hydroxy, cn-y-s (o) 2 - (c
